Cargando…
Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain
SIMPLE SUMMARY: Anti-tumor treatment efficacy is determined by tumor shrinkage, which takes valuable time to become apparent and poses a risk of unnecessary treatment with severe side effects. Therefore, there is an unmet need for more reliable and specific methods to monitor treatment efficacy. We...
Autores principales: | Stroet, Marcus C. M., de Blois, Erik, de Jong, Marion, Seimbille, Yann, Mezzanotte, Laura, Löwik, Clemens W. G. M., Panth, Kranthi M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870237/ https://www.ncbi.nlm.nih.gov/pubmed/35205609 http://dx.doi.org/10.3390/cancers14040861 |
Ejemplares similares
-
In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors
por: Stroet, Marcus C. M., et al.
Publicado: (2021) -
In Vivo Evaluation of Indium-111–Labeled 800CW as a Necrosis-Avid Contrast Agent
por: Stroet, Marcus C. M., et al.
Publicado: (2020) -
Necrosis binding of Ac-Lys(0)(IRDye800CW)-Tyr(3)-octreotate: a consequence from cyanine-labeling of small molecules
por: Stroet, Marcus C. M., et al.
Publicado: (2021) -
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018) -
Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW
por: Amini, Abolfazl, et al.
Publicado: (2022)